ArticleAnnals of medicine2026
Glimepiride alleviates blood-brain barrier disruption and neuroinflammation in mice with intracerebral haemorrhage.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntracerebral haemorrhage (ICH) is characterised by high mortality and lethality with no effective treatment. Studying the pathophysiological mechanism of brain injury after ICH is expected to improve prognosis. Glimepiride (GPD) has neuroprotective effects in ischaemic stroke and Parkinson's disease models. However, it is unclear whether GPD effectively reduces brain injury after ICH. Therefore, we evaluated GPD in acute brain injury in ICH mice and assessed its potential mechanisms.
methodsC57BL/6 mice were injected with collagenase into the right striatum to induce ICH, and were euthanized after 3 days of GPD treatment (4 mg/kg/day). Brain tissues around the haematoma were collected for Western blot and microscopy analyses. The corner turn test, forelimb placing test and modified Garcia test were used to assess neurological functions during life.
resultsThe effectiveness of GPD was demonstrated by improved neurological functions, decreased brain oedema and reduced haematoma volume. GPD upregulated ZO-1 and occludin expression while downregulating MMP-9, indicating that GPD protected the integrity of the blood-brain barrier. This was corroborated by the reduction of albumin and Evans blue leakage into the brain parenchyma of GPD-treated mice. Moreover, the anti-inflammatory efficacy of GPD was suggested by reduced Iba-1 and myeloperoxidase immunohistochemistry. GPD also decreased neuronal apoptosis, as evidenced by the upregulation of BCL-2, downregulation of BAX, and decreased number of TUNEL-positive cells.
conclusionIn ICH injury, GPD protects the integrity of the blood-brain barrier, alleviates neuroinflammation, improves neurological functions, mitigates brain oedema, lessens haematoma volume, and inhibits the apoptosis of neural cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.